TET2-mutant clonal hematopoiesis and risk of gout.
Saved in:
| Title: | TET2-mutant clonal hematopoiesis and risk of gout. |
|---|---|
| Authors: | Agrawal M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Niroula A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of Harvard and MIT, Cambridge, MA.; Department of Laboratory Medicine, Lund University, Lund, Sweden., Cunin P; Division of Immunology, Boston Children's Hospital, Boston, MA., McConkey M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Shkolnik V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Kim PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of Harvard and MIT, Cambridge, MA., Wong WJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of Harvard and MIT, Cambridge, MA., Weeks LD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Lin AE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Broad Institute of Harvard and MIT, Cambridge, MA.; Department of Laboratory Medicine, Lund University, Lund, Sweden.; Division of Immunology, Boston Children's Hospital, Boston, MA.; Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA., Miller PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Gibson CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Sekar A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Schaefer IM; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Neuberg D; Department of Data Science, Dana-Farber Cancer Institute, Boston, MA., Stone RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Bick AG; Division of Genetic Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN., Uddin MM; Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA.; Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA., Griffin GK; Broad Institute of Harvard and MIT, Cambridge, MA.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Jaiswal S; Department of Pathology and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA., Natarajan P; Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA.; Program in Medical and Population Genetics and the Cardiovascular Disease Initiative, Broad Institute of Harvard and MIT, Cambridge, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Nigrovic PA; Division of Immunology, Boston Children's Hospital, Boston, MA.; Division of Rheumatology, Inflammation, Immunity, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and., Rao DA; Division of Rheumatology, Inflammation, Immunity, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and., Ebert BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Howard Hughes Medical Institute, Boston, MA. |
| Source: | Blood [Blood] 2022 Sep 08; Vol. 140 (10), pp. 1094-1103. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
